Clinical Trials Logo

Filter by:
NCT ID: NCT05970783 Recruiting - Chronic Pelvic Pain Clinical Trials

A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease

Start date: November 8, 2022
Phase: Phase 3
Study type: Interventional

The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease

NCT ID: NCT05970705 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the clinical benefit of regorafenib combined with TAS-102 compared with regorafenib monotherapy in patients with metastatic colorectal cancer who have failed at least two lines of treatment, to explore the rationality of this combination therapy strategy and to obtain relevant survival and safety data.

NCT ID: NCT05970666 Recruiting - Clinical trials for Hepatocellular Carcinoma

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Start date: November 15, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma

NCT ID: NCT05970653 Recruiting - Clinical trials for Remote Ischemic Conditioning

Effect of RIC on Cerebral Autoregulation in Patients Undergoing Cerebrovascular Stent Implantation

Start date: August 2, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effect of remote ischemic conditioning on cerebral autoregulation in patients undergoing cerebrovascular stent implantation.

NCT ID: NCT05970627 Not yet recruiting - Clinical trials for Adenocarcinoma of the Stomach

Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Start date: July 28, 2023
Phase: Phase 2
Study type: Interventional

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative SOX combined with toripalimab in participants with Epstein-Barr Virus-associated locally advanced gastric or esophagogastric junction adenocarcinoma.

NCT ID: NCT05970510 Recruiting - Clinical trials for Generalized Anxiety Disorder

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Start date: July 12, 2023
Phase: Phase 3
Study type: Interventional

The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.

NCT ID: NCT05970445 Active, not recruiting - Hearing Loss Clinical Trials

Clinical Phenotypic Characteristics of SC26A4

Start date: May 15, 2023
Phase:
Study type: Observational

The presence or absence of SC26A4, whether combined with Mondini malformation, and patient age, are important factors affecting the degree of hearing loss in the Chinese population.

NCT ID: NCT05970432 Recruiting - Atopic Dermatitis Clinical Trials

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Start date: June 19, 2023
Phase: Phase 2
Study type: Interventional

This phase II clinical trials is multicenter, randomized, double-blind, placebo-controlled to assess the effectiveness and safety of TQH2722 injection in the treatment of subjects with moderate to severe atopic dermatitis.

NCT ID: NCT05970393 Recruiting - Clinical trials for Mechanical Ventilation

Inspiratory Contribution of Pressure Support-ventilated Patients in Different PMI Conditions

Start date: February 7, 2023
Phase: N/A
Study type: Interventional

Pressure support ventilation (PSV) is an assisted mechanical ventilation mode that provides synchronous inspiratory support for patients with spontaneous breathing. PSV divides the work involved in producing ventilation between the ventilator and the patients. The patient inspiratory effort needs close monitoring to avoid inappropriate assistance and maintain favorable patient-ventilator interaction during PSV. Esophageal pressure (Pes)-derived parameters are regarded as golden indicators of inspiratory effort. Based on this precondition, the fraction of PTP generated by the patient during PSV (PTP ratio) can evaluate the inspiratory contribution proportion of ventilated patients with spontaneous breathing. Inspiratory muscle pressure index (PMI) was confirmed to be associated with inspiratory effort and can effectively predict low/high effort. The study tries to explore the relationship between PMI and PTP ratio and find the optimal cut-off value of PMI to predict different PTP ratios. Second, investigators want to verify the safety and validity of PMI-guided PS settings for pressure-support ventilated patients.

NCT ID: NCT05970302 Recruiting - Capecitabine Clinical Trials

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Start date: July 7, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy,in MSS/pMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a "hot tumor" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.